<DOC>
	<DOCNO>NCT02256215</DOCNO>
	<brief_summary>Restless Legs Syndrome ( RLS ) sensorimotor disorder syndrome may substantially interfere normal sleep , lead significant impairment patient ' productivity quality life . The common potent treatment regimens dopaminergic agonist agent , carry serious adverse event prolong use despite augmentation . A basic study suggest potential relationship vitamin D RLS . It implicate dopaminergic system dysfunction play role development RLS , vitamin D protective effect system . This substantiated clinical observation show prompt improvement RLS patient upon receive dopaminergic agent carbamazepine . Other study reveal low serum level vitamin D RLS patient , along remarkable improvement vitamin D replacement therapy , demonstrate recent pilot study . This collectively point vitamin D potential , natural safer treatment option suffer RLS . However , role vitamin D RLS effectively investigate . The aim 12-week , triple-blinded , randomize , placebo-controlled trial confirm relationship vitamin D deficiency RLS hence elucidate efficacy vitamin D replacement therapy reduce severity RLS , prediction result contribute good understand disease management . Methods Materials : This 12-week , double-blinded , randomize , placebo-controlled trial take place duration 2 year . It hold city Jeddah ass sample Saudi resident Western region . It comprise number visit , first one consist questionnaire answer regard RLS , physical examination , electromyography , objective multiple Suggested Immobilization test , blood test . The main purpose second visit establish diagnosis RLS . Clinic visit number 3 6 comprise pre-randomizaiton phase . Their purpose determine patient 's adherence trial procedure pharmacological treatment . Then , patient visit clinic every two week first two month , week 12 . Patients assessed regard treatment response adverse effect history physical examination along blood test . Aim : confirm relationship vitamin D deficiency RLS hence elucidate efficacy vitamin D replacement therapy reduce severity RLS , prediction result contribute good understand disease management .</brief_summary>
	<brief_title>Vitamin D Treatment Primary Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Newly diagnose already diagnosed patient primary RLS vitamin D deficiency . 2 . Patients currently receive treatment RLS vitamin D replacement therapy . 3 . Patients 18 75 year old . 4 . Patients otherwise good general health . 1 . Patients diagnose secondary RLS . i.e . : patient : 1 . Iron deficiency anemia 2 . Endstage renal disease . 3 . Diabetes mellitus ( DM ) . 4 . Peripheral neuropathy . 5 . Multiple sclerosis ( MS ) . 6 . Pregnancy . 2 . Patients mimic disorder primary sleep disorder . E.g . : 1 . Arthritis . 2 . Deep venous thrombosis . 3 . Varicose vein venous insufficiency . 4 . Habitual foot tap . 3 . Patients receive medication trigger RLS . i.e . : 1 . Anti hypertensive medication . E.g . Use thiazide diuretic total dose great 37.5 mg/day . 2 . Anti convulsion medications.e.g . Use anticonvulsant drug start within 6 month screen . Stable regimen anticonvulsant allow . 3 . Antinausea drug ( prochlorperazine metoclopramide ) . 4 . Antipsychotic drug ( haloperidol phenothiazine derivative ) . 5 . Anti depressant ( SSRIs ) . 6 . Antihistamines cold allergy medication . 4 . Patients current medication condition would interfere vitamin D absorption : 1 . Celiac disease . 2 . Chron 's disease . 3 . Chronic pancreatitis . 4 . Cystic fibrosis . 5 . Weightloss drug e.g . orlistat . 6 . Cholesterollowering drug e.g . cholestyramine 5 . Patients contraindication vitamin D supplement . i.e . : 1 . Hyperparathyroidism . 2 . Kidney stone . 3 . Liver disease . 4 . Granulomatous disorder ( sarcoidosis , tuberculosis ) 6 . Patients 17 year old young . 7 . Use supplement contain vitamin D total dose high 1000 IU/day within 12 week baseline visit initiate protocol unwillingness limit vitamin D supplementation dosage high 1000 IU/day duration study . 8 . Use supplement contain calcium total dose high 600 mg/day within 1 week baseline visit initiate protocol unwillingness limit calcium supplementation dosage 600 mg/day duration study . 9 . History intolerance vitamin D supplement . 10 . Women : A. Pregnancy ( past 1 year report positive pregnancy test screening ) , intent become pregnant next 4 year unprotected intercourse . History gestational diabetes exclusion criterion . B . Currently breastfeed . C. Use oral contraceptive menopausal hormone therapy start within 3 month baseline . Stable regimen oral contraceptive hormonal method contraception ( e.g . implantable ) allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Vitamin D</keyword>
</DOC>